Active	Status	Sponsor type	Region	Phase	Filter
6 Active 8 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Curci, John A
stAAAble, NCT06001918: Nectero EAST System Clinical Study	Recruiting	2/3	400	US	Nectero EAST System	Nectero Medical, Inc.	Abdominal Aortic Aneurysm	03/27	12/29
Chen, Delphine L
iPREDICT, NCT05013099 / 2021-005610-33: Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies	Active, not recruiting	2	70	Europe, US, RoW	zirconium Zr 89 crefmirlimab berdoxam, 89Zr-Df-crefmirlimab, 89Zr-Df-IAB22M2C	ImaginAb, Inc.	Melanoma, Merkel Cell Carcinoma, Unspecified, Renal Cell Carcinoma, Non Small Cell Lung Cancer	07/25	07/25
NCT06129422: Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer	Recruiting	1	10	US	NMK89	Nihon Medi-Physics Co., Ltd.	Pancreatic Cancer	03/25	03/25
NCT06147037: A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumours	Recruiting	1	110	Canada, US	FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068	Fusion Pharmaceuticals Inc., AstraZeneca	Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma	12/26	12/27